Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Rises 16% – Tale of the Tape

Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise more than 16% on the day. The upside came on the back of the company’s announcement that Moshe Manor, its President and Chief Executive Officer, will present a corporate overview at 33rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2015. This led to more shares changing hands than in a normal session, breaking the recent trend for the company, as the stock is now trading above the volatile price range of $1.80 to $2.14 in the past one-month time frame.

None of the estimates for this stock were revised in the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Protalix BioTherapeutics carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A better-ranked stock in the in the med-biomed/gene industry is Affymetrix Inc. (AFFX), sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>